Optimal Treatment of Unresectable Locally Advanced NSCLC. Sponsored by a Grant from the Bonnie J. Addario Lung Cancer Foundation
|
|
|
- Agatha Williams
- 5 years ago
- Views:
Transcription
1 Optimal Treatment of Unresectable Locally dvanced SCLC Howard (Jack) West, M Medical Oncologist Medical irector, Thoracic Oncology Program Swedish Cancer Institute Seattle, W February, 2009 President & CEO GCE Sponsored by a Grant from the Bonnie J. ddario Lung Cancer Foundation Working to eradicate lung cancer through research, early detection, education, prevention, and treatment. For information about sponsoring a presentation about a topic important to you, please info@cancergrace.org
2 isclaimers The information provided here includes views of the presenter that do not necessarily represent those of the Global esource for dvancing Cancer Education (GCE) in general, nor those of Swedish Cancer Institute. The contents of this program do not constitute medical advice and is intended to supplement but not replace input from an individual patient s own medical team. Stage III/Locally dvanced SCLC pproximately 40-45% of new presentations of SCLC
3 Efficacy esults: Sequential vs. Concurrent Chemoradiotherapy, Two Major Trials West Japan TOG 9410 MVP* T x2 56 Gy St III SCLC = MVP* x 2 Concurrent T 56 Gy (split course) MVP* = mitomycin C, vinblastine, cisplatin St III SCLC = Cis/ VBL x2 T 63 Gy Cis/VBL x2 concurrent T daily Cis/Etop (PO) x2 concurrent 2x/d T 5-year OS (%) % 9% Seq Conc Furuse, JCO 17: , year OS (%) % 17% 12% Seq Conc HyperFx Curran, PSCO 22:621. #2499, 2003 Survival Comparison between Sequential and Concurrent CT/T (n=709) WJLCG GLOT (n=716) CZECH LMP TOG 9410 BOCT 10 Sequential Concurrent Choy, SCO 2003 P < 0.05 (Kruskal-Wallis Test)
4 Early Toxicity Comparison between Sequential and Concurrent CT/T % WJLCG GLOT CZECH LMP % TOG 9410 BOCT 0 Sequential Concurrent SWOG 9504: Consolidation Taxotere (ocetaxel) after efinitive Chemoradiation =83 evaluable, stage IIIB SCLC Overall Survival Cisplatin/Etoposide x2 cycles with concurrent T 61Gy Progression-FreeSurvival Taxotere every three weeks x3 cycles, consolidation chemo Gandara, J Clin Oncol, 2003 Failure in brain 33%
5 Hoosier Oncology Group (HOG) Trial: irect Test of Consolidation Taxotere (ocetaxel) Unresectable Stage III SCLC Cisplatin/etoposide x2 w/concurrent XT to 61 Gy o P PS 0-2 Consolidation Taxotere every 3 weeks x 3 cycles Observation ccrued: 203 pts 147 pts (68%) Hanna, J Clin Oncol 2008 HOG Trial: Overall Survival Hanna, J Clin Oncol 2008
6 HOG Trial: Side Effects and Treatment-elated eaths Hanna, J Clin Oncol 2008 Chemo/adiation Consolidation Taxotere (ocetaxel) Maintenance Iressa (Gefitinib) vs. Placebo Unresectable Stage III/IIIB Cisplatin/ etoposide x2 w/concurrent XT 61 Gy Taxotere (ocetaxel) 75 mg/m2 x 3 cycles Iressa (Gefitinib) 500/250 mg PO daily Placebo PO daily ccrued: 620 pts 574 pts (74%) 263 pts (42%) Eligible: 575 pts 412 pts (72%) 255 pts (44%) Kelly, J Clin Oncol 2008
7 SWOG 0023: Efficacy Progression-Free Survival Overall Survival Kelly, J Clin Oncol 2008 TOG/Intergroup Trial of Chemo/adiation to Either 60 or 74 Gray, +/- Erbitux (Cetuximab) Primary Endpoint: Overall Survival Unresectable Stage III SCLC, = 512 = 512 T to 60 Gy T to 74 Gy Concurrent Chemo/adiation weekly adiation to 60 Gy + Erbitux (cetuximab) weekly weekly adiation to 60 Gy weekly adiation to 74 Gy + Erbitux (cetuximab) weekly weekly adiation to 74 Gy Consolidation every 3 wks every 3 wks every 3 wks every 3 wks
8 Eli Lilly-Sponsored Phase III Trial in Stage III Unresectable SCLC Concurrent Chemo/adiation Consolidation Unresectable Stage III SCLC, on-squamous = 600 O M I Z E Cisplatin IV d1 limta IV d1 every weeks x 3 adiation 66 Gy/33 Fx Cisplatin d1,8 Etoposide d1-5 Q4 weeks x 2 adiation 66 Gy/33 Fx limta IV d1 x3 cycles Cis/Etoposide or Cis/avelbine or Primary Endpoint: Overall Survival (superiority) Conclusions: Optimal Therapy for Stage III Unresectable SCLC, Today Concurrent chemo/t consistently superior to sequential chemo/t espite encouraging results from SWOG phase II S9504 trial, neither HOG trial nor SWOG 0023 trial demonstrates benefit with consolidation Maintenance EGF inhibitor after chemo/t and consolidation chemo was significantly detrimental in unselected population Current controversies/questions: Is 6-7 weeks of plat-based CT with T to Gy is enough?! We don t have compelling evidence that more chemo is better Many oncologists still feel additional chemo is likely beneficial ew trials exploring alimta (non-squamous patients only) and erbitux, higher radiation doses, and other agents
9 Questions and Comments? Posts with additional detail on these topics are available at GCE members can leave comments and questions at
Slide 1 Combined Chemotherapy and Radiation Therapy for Locally Advanced NSCLC. Slide 2. Slide 3 Options for Locally Advanced NSCLC
Slide 1 Combined Chemotherapy and adiation Therapy for Locally dvanced SCLC George. Blumenschein, Jr., M ssociate Professor of Medicine epartment of Thoracic/Head & eck Medical Oncology The University
Two Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
Combined Chemotherapy and Radiation Therapy for Locally Advanced NSCLC
Combined Chemotherapy and Radiation Therapy for Locally Advanced NSCLC George R. Blumenschein, Jr., MD Associate Professor of Medicine Department of Thoracic/Head & Neck Medical Oncology The University
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
11/21/2009. Early Stage. Stage III. From Mountain: Chest, 1997
Combined odality egimens in Locally dvanced SCLC: Current Status and Future irections Primo. Lara, Jr, Professor of edicine University of California avis Cancer Center arly Stage Stage Five-Year Survival
Stage III NSCLC: Overview
Locally Advanced NSCLC: New Concepts in Combined Modality Therapy NSCLC: Stage Distribution Randeep Sangha, MD Visiting Assistant Professor UC Davis Cancer Center Sacramento, CA Stage III NSCLC: Overview
Heterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
The ABCs of BAC: Bronchioloalveolar Carcinoma
The ABCs of BAC: Bronchioloalveolar Carcinoma Howard (Jack) West, MD Medical Oncologist Medical Director, Thoracic Oncology Program Swedish Cancer Institute Seattle, WA March, 2009 President & CEO GRACE
Lung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
Combined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
CANCER TREATMENT REGIMENS
CANCER TREATMENT S Lung Cancer The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Drug dose modifications and schedule and initiation
Combined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
CALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
Update on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Update on Limited Small Cell Lung Cancer Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Objectives - Limited Radiation Dose Radiation Timing Radiation Volume PCI Neurotoxicity
What is Next for Patients with Stage III Non-Small Cell Lung Cancer?
What is Next for Patients with Stage III Non-Small Cell Lung Cancer? Walter J Curran, Jr, MD Executive Director Winship Cancer Institute of Emory University Atlanta, GA NRG Oncology Group Chairman 1 Stage
Multidisciplinary interactive session (MIS) pn2: The optimal treatment in Wilfried Ernst Erich Eberhardt
Multidisciplinary interactive session (MIS) pn2: The optimal treatment in 2012 Wilfried Ernst Erich Eberhardt Department of Medicine (Cancer Res.), University Hospital Essen, West German Cancer Centre,
Practice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small cell lung cancer?
Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small cell lung cancer? ~A pooled analysis of the literature~ Satomi Yamamoto 1, Kazuyuki
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
Targeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
Combining chemotherapy and radiotherapy of the chest
How to combine chemotherapy, targeted agents and radiotherapy in locally advanced NSCLC? Dirk De Ruysscher, MD, PhD Radiation Oncologist Professor of Radiation Oncology Leuven Cancer Institute Department
Debate on stage III NSCLC: The role of systemic therapy
1 Debate on stage III NSCLC: The role of systemic therapy Rolf Stahel University Hospital of Zürich Bucharest, 16.6..2015 2 Stage III disease: The problem of heterogeneity, the risk of distant metastases
ENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias. Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA
ENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA Formigal, 28 de Junio de 2018 CÓMO DEFINÍAMOS EL ESTADIO
Disclosures. Preoperative Treatment: Chemotherapy or ChemoRT? Adjuvant chemotherapy helps. so what about chemo first?
Disclosures Preoperative Treatment: Chemotherapy or ChemoRT? Advisory boards Genentech (travel only), Pfizer Salary support for clinical trials Celgene, Merck, Merrimack Matthew Gubens, MD, MS Assistant
肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部
肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部 Outline Current status of radiation oncology in lung cancer Focused on stage III non-small cell lung cancer Radiation
RTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman
RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG
Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
Lung cancer update 2007
Lung cancer update 2007 HARMESH R NAIK, MD. January 24, 2007 Epidemiology (world) Estimated 1.35 million new cases in world in 2002 Estimated 1.179 million deaths in world in 2002 Common cancer diagnosis
Concurrent and sequential chemoradiotherapy. P. Van Houtte Department of Radiation Oncology Institut Jules Bordet
Concurrent and sequential chemoradiotherapy and radiotherapy for NSCLC P. Van Houtte Department of Radiation Oncology Institut Jules Bordet RADIOTHERAPY & CHEMOTHERAPY A very old concept «Benzene could
Casi clinici di integrazione multiprofessionale: NSCLC stadio III. Biagio Ricciuti. Scuola di Specializzazione in Oncologia Medica
Casi clinici di integrazione multiprofessionale: NSCLC stadio III Scuola di Specializzazione in Oncologia Medica Università degli Studi di Perugia Outline Standard treatment Open questions Clinical cases
EGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
Advances in Chemotherapy for Non-Small Cell Lung Cancer
Advances in Chemotherapy for Non-Small Cell Lung Cancer Evan W. Alley, MD, PhD Clinical Associate Professor Abramson Cancer Center at Penn Presbyterian Lung Cancer: Overview Second most common cancer in
ES-SCLC Joint Case Conference. Anthony Paravati Adam Yock
ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar
LUNG CANCER. Başak Oyan-Uluç, MD Yeditepe University Hospital Medical Oncology. Best of ASCO, İstanbul
LUNG CANCER Başak Oyan-Uluç, MD Yeditepe University Hospital Medical Oncology Best of ASCO, İstanbul 2012 23.6.2012 Treatment of Metastatic NSCLC EGFR targetted treatments 1st line: EGFR-mutated: Afatinib
Integrating Targeted Agents into Combined Modality Therapy in LA-NSCLC A 2012 Perspective
Integrating Targeted Agents into Combined Modality Therapy in LA-NSCLC A 2012 Perspective Corey J. Langer, M.D. Vice Chair, RTOG Director Thoracic Oncology Abramson Cancer Center Professor of Medicine
Single Technology Appraisal (STA)
Single Technology Appraisal (STA) Durvalumab for maintenance treatment of locally advanced unresectable non-small cell lung cancer that has not progressed after platinum-based chemoradiation therapy Response
Cooperative Group Update - Japan; JCOG & WJOG -
Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine, Yokohama City University Chief, Division of Thoracic Surgery, Respiratory Disease Center
Current Approaches for Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Current Approaches for Limited Small Cell Lung Cancer Laurie Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Can we improve or personalize treatment? Limited Histology/molecular
Slide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
Treatment of LS (Stage I-III) SCLC
Treatment of LS (Stage I-III) SCLC Prof C Faivre-Finn Manchester Lung Cancer Group Manchester Radiation Related Research Group ESMO-The Christie Preceptorship programme on Lung Cancer 9 th March 2018 @finn_corinne
De-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
Thoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
Locally advanced unresectable non small cell lung cancer
ORIGINAL ARTICLE Docetaxel Consolidation Therapy Following Cisplatin, Vinorelbine, and Concurrent Thoracic Radiotherapy in Patients with Unresectable Stage III Non-small Cell Lung Cancer Ikuo Sekine,*
Second-line treatment for advanced NSCLC
Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY DISCLOSURE OF INTEREST Speaker Bureau: Eli Lilly, MSD, BI, BMS, Roche, AZ UNIVERSITY
1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
National Horizon Scanning Centre. Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer
Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer This technology summary is based on information available at the time of research and a limited
Pre- Versus Post-operative Radiotherapy
Postoperative Radiation and Chemoradiation: Indications and Optimization of Practice Dislosures Clinical trial support from Genentech Inc. Sue S. Yom, MD, PhD Associate Professor UCSF Radiation Oncology
Chapter 5 Stage III and IVa disease
Page 55 Chapter 5 Stage III and IVa disease Overview Concurrent chemoradiotherapy (CCRT) is recommended for stage III and IVa disease. Recommended regimen for the chemotherapy portion generally include
Adjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support
Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no
Induction Chemoradiation Therapy with Cisplatin plus Irinotecan Followed by Surgical Resection for Superior Sulcus Tumor
Original Article Induction Chemoradiation Therapy with Cisplatin plus Irinotecan Followed by Surgical Resection for Superior Sulcus Tumor Katsuhiko Shimizu, 1 Masao Nakata, 1 Ai Maeda, 1 Takuro Yukawa,
Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy fortune favours the bold
Editorial Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy fortune favours the bold Surein Arulananda 1,2,3, Paul Mitchell 1,3,4 1 Cancer Immuno-Biology Laboratory,
Carcinoma del Canale Anale. Approcci RadioChemioterapici. Antonino De Paoli.. Oncologia Radioterapica, CRO Aviano.
Carcinoma del Canale Anale Approcci RadioChemioterapici Antonino De Paoli.. Oncologia Radioterapica, CRO Aviano. Anal Cancer Epidemiology and Risk Factors Uncommon Disease; 2-4% of all GI Tumors Increasing
The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology
The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology (specifically, lung cancer) 2/10/18 Jeffrey Kittel, MD Radiation Oncology, Aurora St. Luke s Medical Center Outline The history
Small Cell Lung Cancer What we have now?
Small Cell Lung Cancer What we have now? Chunxue Bai, M.D., Ph.D. Chair, Chinese Alliance against Lung Cancer Shanghai Respiratory Research Institute Department of Pulmonary Medicine Zhongshan Hospital,
Oncologist. The. ASCO 1999: Critical Commentaries. Lung Cancer Highlights THOMAS J. LYNCH, JR. The Oncologist 1999;4:
The Oncologist ASCO 1999: Critical Commentaries Lung Cancer Highlights THOMAS J. LYNCH, JR. Massachusetts General Hospital, Boston, Massachusetts, USA Adjuvant therapy does not work. Second-line therapy
The population of patients with stage III non
GREGORY M.M. VIDETIC, MD, CM, FRCPC Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH Locally advanced non small cell lung cancer: What is the optimal concurrent
NRG Oncology Lung Cancer Portfolio 2016
NRG Oncology Lung Cancer Portfolio 2016 Roy Decker, MD PhD Yale Cancer Center Walter J Curran, Jr, MD Winship Cancer Institute of Emory University NRG Oncology Lung Cancer Selected Discussion Stage III
Adjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
Optimal sequencing in treatment muscle invasive bladder cancer : oncologists. Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University
Optimal sequencing in treatment muscle invasive bladder cancer : oncologists Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Slide 2 Presented By Andrea Apolo at 2018 Genitourinary Cancers
The 2010 Gastrointestinal Cancers Symposium Oral Abstract Session: Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract
The 2010 Gastrointestinal Cancers Symposium : Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract Abstract #131: Phase I study of MK 0646 (dalotuzumab), a humanized monoclonal antibody against
Is the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials
Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized
Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage
Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: TBD003/01/201703/01/2018 POLICY A. INDICATIONS The indications
Cancer Biology 2016;6(1)
Weekly Docetaxel and Cisplatin with Concomitant Radiotherapy in Addition to Consolidation Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer Hanan G. Mostafa and Mohamed-Alaaeldeen H. Mohamed
HPV VACCINE AND AIN Palefsky NEJM 2011 n=602 MSM 16-26y qhpv = vaccine against HPV 6, 11, 16 and 18 vs placebo They analyzed ITT and per protocol.
ANAL CANCER Updated Mar 2017 by Doreen Ezeife, PGY-5 resident University of Calgary Reviewed by Dr. Lee-Ying (Staff Medical Oncologist, University of Calgary), Dr. Kzyzanowska (Staff Medical Oncologist,
The Role of Thoracic Radiotherapy as an Adjunct to Standard Chemotherapy in Limited-Stage Small Cell Lung Cancer
Evidence-based Series # 7-13-3 EDUCATION AND INFORMATION 2013 The Role of Thoracic Radiotherapy as an Adjunct to Standard Chemotherapy in Limited-Stage Small Cell Lung Cancer Members of the Lung Cancer
Tratamiento Multidisciplinar del CNMP Localmente Avanzado. Luis Paz-Ares
Tratamiento Multidisciplinar del CNMP Localmente Avanzado Luis Paz-Ares Indice Definición & Estadios Estadio IIIA N2 Estadio IIIB (y N2 irresecables) Conclusiones Indice Definición & Estadios Estadio IIIA
Combining Lurbinectedin and Doxorubicin The UCLH Experience in Small Cell Lung Cancer
Combining Lurbinectedin and Doxorubicin The UCLH Experience in Small Cell Lung Cancer Dr Martin Forster MD PhD Clinical Senior Lecturer in Experimental Cancer Medicine Consultant in Medical Oncology UCL
Chemo-radiotherapy in non-small cell lung cancer. HARMESH R NAIK, MD. September 25, 2002
Chemo-radiotherapy in non-small cell lung cancer HARMESH R NAIK, MD. September 25, 2002 Epidemiology Estimated 170000 new cases Estimated 157,000 deaths Second commonest cancer diagnosis in men and women
Approximately one third of patients with non-small cell. Locally Advanced Non-small Cell Lung Cancer: The Past, Present, and Future
STATE OF THE ART: CONCISE REVIEW Locally Advanced Non-small Cell Lung Cancer: The Past, Present, and Future Ramaswamy Govindan, MD,* Jeffrey Bogart, MD, and Everett E. Vokes, MD Abstract: Approximately
SCLC: Developments in systemic treatment
SCLC: Developments in systemic treatment Egbert F. Smit, Dept. Pulmonary Diseases, Vrije Universiteit Medisch Centrum, Amsterdam, The Netherlands Staging Outline First line treatment Second line treatment
Concurrent chemoradiotherapy (CCRT) is considered
ORIGINAL ARTICLE Tumor Cavitation in Patients With Stage III Non Small-Cell Lung Cancer Undergoing Concurrent Chemoradiotherapy Incidence and Outcomes Erik C. J. Phernambucq, MD,* Koen J. Hartemink, MD,
The Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance
The Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance H. Jack West, MD Swedish Cancer Institute Seattle, WA GRACE Targeted Therapies Forum September 16, 2017 Cleveland, OH EGFR Mutation-Positive
doi: /theoncologist originally published online February 3, 2009
Potential Treatment Options After First-Line Chemotherapy for Advanced NSCLC: Maintenance Treatment or Early Second-Line? Cesare Gridelli, Paolo Maione, Antonio Rossi, Marianna Luciana Ferrara, Maria Anna
The PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer
The PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer Robert I. Haddad, Guilherme Rabinowits, Roy B. Tishler,
Naoya Hida Hiroaki Okamoto Yuuki Misumi Akira Sato Mari Ishii Fumihiro Kashizaki Tsuneo Shimokawa Teppei Shimizu Koshiro Watanabe
Cancer Chemother Pharmacol (2012) 69:1625 1631 DOI 10.1007/s00280-012-1871-5 ORIGINAL ARTICLE A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for
Debate 1 Are treatments for small cell lung cancer getting better? No:
Debate 1 Are treatments for small cell lung cancer getting better? No: Taofeek Owonikoko, MD, PhD Associate Professor Department of Hematology & Medical Oncology Winship Cancer Institute of Emory University
ANAL CANCER Updated May 2016 by Dr. Daniel Yokom (PGY-5 Medical Oncology Resident, University of Toronto)
ANAL CANCER Updated May 2016 by Dr. Daniel Yokom (PGY-5 Medical Oncology Resident, University of Toronto) Reviewed by Dr. Lee-Ying (Staff Medical Oncologist, University of Calgary), Dr. Kzyzanowska (Staff
LUNG CANCER. Agnieszka Słowik, MD. Department of Oncology, University Hospital in Cracow Jagiellonian University
LUNG CANCER Agnieszka Słowik, MD Department of Oncology, University Hospital in Cracow Jagiellonian University Epidemiology Most common malignancy worldwide Place of lung cancer among other malignancies
Cetuximab in non-small-cell lung cancer
Review Article Cetuximab in non-small-cell lung cancer Robert Pirker, Martin Filipits Department of Medicine I, Medical University Vienna, 1090 Vienna, Austria Corresponding to: Robert Pirker, MD. Department
Treatment of Stage I-III SCLC
Treatment of Stage I-III SCLC Prof C Faivre-Finn Manchester Lung Cancer Group Manchester Radiation Related Research Group ESMO-The Christie Preceptorship programme on Lung Cancer 3 rd March 2017 @finn_corinne
Neoplasie del laringe Diagnosi e trattamento
Neoplasie del laringe Diagnosi e trattamento Venerdì 22 maggio 2015 Alessandria Trattamenti non chirurgici: Preservazione d organo, malattia localmente avanzata Marco C Merlano A.O. S.Croce e Carle, Ospedale
Oncologist. The. ASCO 2000: Critical Commentaries. Lung Cancer Highlights THOMAS J. LYNCH, JR. ABSTRACT
The Oncologist ASCO 2000: Critical Commentaries Lung Cancer Highlights THOMAS J. LYNCH, JR. Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA Key Words. Small cell lung cancer Non-small
LUNG CANCER Incidence of major histologic types*
LUNG CANCER Incidence of major histologic types* 5% other Small-cell carcinoma Adenocarcinoma 15% Large-cell carcinoma Adapted from Ihde DC, et al. Cancer: Principles & Practice of Oncology. 5th ed. 1997.
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
EGFR Mutation-Positive Acquired Resistance: Dominance of T790M
Treatment of EGFR Mutation-Positive Acquired Resistance: T790M+ or T790M- H. Jack West, MD Swedish Cancer Institute, Seattle, WA EGFR Mutation-Positive Acquired Resistance: Dominance of T790M Yu, Clin
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
Hot topics in Radiation Oncology for the Primary Care Providers
Hot topics in Radiation Oncology for the Primary Care Providers Steven Feigenberg, MD Professor Chief, Thoracic Oncology Vice Chair of Clinical Research April 19, 2018 Disclosures NONE 2 Early Stage Disease
doi: /j.ijrobp
doi:10.1016/j.ijrobp.2010.09.004 Int. J. Radiation Oncology Biol. Phys., Vol. 82, No. 1, pp. 425 434, 2012 Copyright Ó 2012 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/$ - see front
5/20/ ) Haffty GB: Concurrent chemoradiation in the treatment of head and neck cancer. Hematol. Oncol. Clin: North Am.
Prague, 24-25 25 April 29 ALTERNATING CHEMORADIATION: FOR WHOM? M. Merlano MD Holy Cross Gen. Hospital Cuneo - Italy ALTERNATING CHEMORADIATION: FOR WHOM? Definition of alternating chemoradiation Targets
Volunteer for Clinical Research
Volunteer for Clinical Research ABOUT RESOURCES CLINICAL RESEARCH FIND STUDIES Clicking on ABOUT brings to this track of information about Clinical Research Clinical Research Research on human volunteers
1 Oregon Health & Science University, Portland, OR 2 Stritch School of Medicine, Loyola University Chicago, Chicago, IL
Current treatment practices for limited-stage small cell lung cancer: A survey of US radiation oncologists on the timing of thoracic radiotherapy with chemotherapy Matthew J. Farrell 1, Jehan Yahya 1,
Ramesh Rengan MD PhD Department of Radiation Oncology University of Washington ASTRO Spring Refresher Course March 8, 2014
The Management of Lung Cancer Ramesh Rengan MD PhD Department of Radiation Oncology University of Washington ASTRO Spring Refresher Course March 8, 2014 Overview Introduction Screening and Workup Early
The standard treatment modality in patients with unresectable
ORIGINAL ARTICLE S-1 Plus Cisplatin with Concurrent Radiotherapy for Locally Advanced Non-small Cell Lung Cancer A Multi-Institutional Phase II Trial (West Japan Thoracic Oncology Group 3706) Yukito Ichinose,
11/21/2009. Erlotinib in KRAS Mt patients. Bevacizumab in Squamous patients
Decision-Making in Non-Small Cell Lung Cancer (NSCLC): Moving from Empiric to Personalized & Molecular-based Therapy David R. Gandara, MD University of California Davis Cancer Center Disclosures Research
Supplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: James RD, Glynne-Jones R, Meadows HM, et al.